Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program
Sun-Mi Park, … , Christopher J. Lengner, Michael G. Kharas
Sun-Mi Park, … , Christopher J. Lengner, Michael G. Kharas
Published February 9, 2015
Citation Information: J Clin Invest. 2015;125(3):1286-1298. https://doi.org/10.1172/JCI78440.
View: Text | PDF
Research Article Oncology

Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program

  • Text
  • PDF
Abstract

Leukemia stem cells (LSCs) are found in most aggressive myeloid diseases and contribute to therapeutic resistance. Leukemia cells exhibit a dysregulated developmental program as the result of genetic and epigenetic alterations. Overexpression of the RNA-binding protein Musashi2 (MSI2) has been previously shown to predict poor survival in leukemia. Here, we demonstrated that conditional deletion of Msi2 in the hematopoietic compartment results in delayed leukemogenesis, reduced disease burden, and a loss of LSC function in a murine leukemia model. Gene expression profiling of these Msi2-deficient animals revealed a loss of the hematopoietic/leukemic stem cell self-renewal program and an increase in the differentiation program. In acute myeloid leukemia patients, the presence of a gene signature that was similar to that observed in Msi2-deficent murine LSCs correlated with improved survival. We determined that MSI2 directly maintains the mixed-lineage leukemia (MLL) self-renewal program by interacting with and retaining efficient translation of Hoxa9, Myc, and Ikzf2 mRNAs. Moreover, depletion of MLL target Ikzf2 in LSCs reduced colony formation, decreased proliferation, and increased apoptosis. Our data provide evidence that MSI2 controls efficient translation of the oncogenic LSC self-renewal program and suggest MSI2 as a potential therapeutic target for myeloid leukemia.

Authors

Sun-Mi Park, Mithat Gönen, Ly Vu, Gerard Minuesa, Patrick Tivnan, Trevor S. Barlowe, James Taggart, Yuheng Lu, Raquel P. Deering, Nir Hacohen, Maria E. Figueroa, Elisabeth Paietta, Hugo F. Fernandez, Martin S. Tallman, Ari Melnick, Ross Levine, Christina Leslie, Christopher J. Lengner, Michael G. Kharas

×

Figure 1

MSI2-bound mRNAs are enriched for experimentally derived MLL transcriptional target genes.

Options: View larger image (or click on image) Download as PowerPoint
MSI2-bound mRNAs are enriched for experimentally derived MLL transcripti...
(A) GSEA plot shows MSI2 rank list of HITS-CLIP targets overlapping with MLL-AF9–controlled genes (FLAG-MSI2–bound mRNAs overlapped with indicated gene sets as performed in ref. 16). (B) GSEA plot with MLL-AF9 direct transcriptional chromatin immunoprecipitated targets, same as A. (C) GSEA of MLL-AF4 targets overlapped with HITS-CLIP targets same as in A. (D) MLL-AF9 primary leukemia cells were stained with indicated antibodies and gated. (E) Representative flow cytometric plot showing MSI2 intracellular staining in gating of c-Kithi and c-Kitlo cells. (F) Frequency of MSI2hi cells in c-Kithi and c-Kitlo population. Experiments (D–F) include samples from 2 independent transplants. n = 9 mice. Means and SEM, *P < 0.05., unpaired Student’s t test.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts